Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMN-101 in Campylobacter jejuni challenge
NCT04182490Phase 2Completed
- Sponsor
- Lumen Bioscience
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in campylobacteriosis comparing LMN-101 3000mg with Placebo (2 arms). Primary endpoint: Number of Participants With Solicited or Unsolicited Adverse Events. Started Feb 2022; status: completed.
02
Drugs
LMN-101
03
Conditions
campylobacteriosis
Beyond the preview
Go deeper on NCT04182490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182490.